The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Takeda’s NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (Rd) for the treatment of multiple myeloma patients who have received two or three prior lines of therapy.
The combination is now available on the Cancer Drugs Fund (CDF).
This landmark decision will mean that multiple myeloma patients in England will now have access to a novel medicine prescribed alongside the two-drug current standard of care.
A number of trials have shown that patients treated with a novel three-drug combination may live longer without their disease worsening, when compared to two-drug combinations.
Over the past 20 months several novel triplet regimens (combined with Rd) have been approved by the European Medicines Agency and these are becoming the new standard of care in Europe and the US. However, IRd is the first novel Rd-based triplet to have access in the UK via the CDF.
There are approximately 1700 myeloma patients in England6 who could potentially benefit from today’s decision. It follows overwhelming support from the myeloma community in response to draft guidance, voicing their opinion that the combination of IRd fulfils an important unmet medical need.
Rosemarie Finley, Chief Executive at Myeloma UK said: “The fact that this is the first oral treatment of its kind, and the first novel Rd based triplet combination to be available, makes this truly a landmark decision. We are grateful for the commitment shown by Takeda, NICE and NHS England to working together to deliver access via the Cancer Drugs Fund. It will make a real positive difference to patients’ lives.”
Dion Warren, Vice President, Head of Oncology Business Unit, Europe & Canada at Takeda Pharmaceuticals, said: “The NICE decision to include ixazomib in the CDF is a real win for the myeloma community. This is a significant step in the right direction for England to catch up with the rest of the developed world in offering effective medicines to multiple myeloma patients.”
Adam Zaeske, Managing Director UK & Ireland at Takeda UK Ltd adds: “We thank the myeloma community for their overwhelming support, which has helped make today a reality.”